Strengthening Regulatory Oversight: India Proposes Strict Advertising Bans on Prescription Drugs for Retailers and Wholesalers

The Union Ministry of Health and Family Welfare has taken a decisive step toward tightening control over pharmaceutical marketing by proposing stringent regulations on the advertisement of prescription medicines by retail chemists, wholesalers, and other distribution entities. Announced via Gazette Notification G.S.R. 861(E), the draft amendment to the Drugs Rules, 1945, seeks to close existing regulatory gaps across the pharmaceutical supply chain and curb inappropriate self-medication practices.

Extending Advertising Restrictions Across the Supply Chain

Previously, strict advertising prohibitions for regulated medicines were primarily targeted at pharmaceutical manufacturers. Under the newly proposed sub-rule (22) under Rule 65 of the Drugs Rules, 1945, these restrictions will explicitly extend to all holders of drug sale and distribution licenses.

The proposed provision mandates that no advertisements for specific scheduled medicines can be carried out without the prior formal sanction of the Central Government. This ensures that retail and wholesale entities cannot independently promote restricted pharmaceutical products directly to the public or through trade channels without central authorization.

Scope of the Regulated Schedules

The proposed amendments cover three distinct categories of medicines under the Drugs Rules, 1945, where medical oversight is critical for public safety:

Schedule H: Prescription drugs that are legally subject to specified sale restrictions and require dispensing under professional medical supervision.
Schedule H1: Specialized medicines—including critical antibiotics and other designated drugs—that require rigorous additional prescriptions and meticulous record-keeping.
Schedule X: Highly controlled substances subject to exceptionally stringent regulations on sale, distribution, and record-keeping to prevent misuse.

The ministry has clarified that this proposal focuses exclusively on advertising and promotional controls. It does not alter the underlying medical prescription, dispensing, or general sale requirements already mandated for these drugs.

Background and Stakeholder Engagement

The initiative stems from key recommendations deliberated at the 93rd meeting of the Drugs Technical Advisory Board (DTAB), held on 16 February 2026. By addressing potential loopholes utilized in unauthorized pharmaceutical promotion, the government aims to safeguard public health against the risks associated with improper self-medication.

In adherence to standard legislative procedure, the Ministry has opened the draft rules to public scrutiny. Stakeholders, industry participants, and the general public have a 30-day window from the date of the Gazette notification to submit their official objections and suggestions. Final implementation and the exact scope of the amendment will be determined after the government reviews these submissions.